These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28117517)

  • 1. Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?
    Alarid-Escudero F; Blaes AH; Kuntz KM
    Breast J; 2017 Jul; 23(4):401-409. PubMed ID: 28117517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.
    Elkin EB; Weinstein MC; Kuntz KM; Bunnell CA; Weeks JC
    Breast Cancer Res Treat; 2005 Sep; 93(1):25-34. PubMed ID: 16184455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy.
    Abdel-Rahman O
    Breast Cancer; 2018 Nov; 25(6):723-728. PubMed ID: 29882200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?
    Simes RJ; Coates AS
    J Natl Cancer Inst Monogr; 2001; (30):146-52. PubMed ID: 11773309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    Breast Cancer Res Treat; 2012 Sep; 135(2):335-46. PubMed ID: 22689092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
    Desch CE; Hillner BE; Smith TJ; Retchin SM
    J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
    Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
    Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.
    Waks AG; Tolaney SM; Galar A; Arnaout A; Porter JB; Marty FM; Winer EP; Hammond SP; Baden LR
    Breast Cancer Res Treat; 2015 Nov; 154(2):359-67. PubMed ID: 26420402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.